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This study evaluated the in vivo antitumor potential of the recombinant lectin from
seeds of Cratylia mollis (rCramoll) expressed in Escherichia coli, free or encapsulated
in stealth liposomes, using mice transplanted with sarcoma 180. rCramoll-loaded stealth
liposomes (rCramoll-lipo) were formulated by hydration of the lipid film followed by cycles
of freezing and thawing, and about 60% of rCramoll was encapsulated. This novel
preparation showed particle size, polydispersity index, and pH suitable for the evaluation
of antitumor activity in vivo. Tumor growth inhibition rates were 59% for rCramoll and
75% for rCramoll-lipo. Histopathological analysis of the experimental groups showed
that both free and encapsulated lectin caused no changes in the kidneys of animals.
Hematological analysis revealed that treatment with rCramoll-lipo significantly increased
leukocyte concentration when compared with the untreated and rCramoll group. In
conclusion, the encapsulation of rCramoll in stealth liposomes improves its antitumor
activity without substantial toxicity; this approach was more successful than the previous
results reported for pCramoll loaded into conventional liposomes. At this point, a crucial
difference between the antitumor action of free and encapsulated rCramoll was found
along with their effects on immune cells. Further investigations are required to elucidate
the mechanism(s) of the antitumor effect induced by rCramoll.
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INTRODUCTION
Cancer is a set of more than 100 pathologies with a related
feature: genetic mutations result in an uncontrollable growth of
cells that can invade tissues and organs (Ryan and Bernstein,
2012). The World Health Organization estimates that 17 million
people will die of cancer in 2030. The battle against a disease of
this magnitude comprises: (i) finding the right target for tumor
inhibition; (ii) discovering drugs that effectively treat this disease;
and (iii) developing the most successful form to transport this
drug (Danhier et al., 2010).
Various plant-derived compounds are potential candidates
for treatment of cancer, such as lectins, a very large class of
proteins, which bind specifically and reversibly to carbohydrate
residues (Da Silva and Correia, 2014). For years, these proteins
have been used as a tool to differentiate benign from malignant
tumors, by assessing alterations in the glycosylation pattern
between normal and cancer cells (Ghazarian et al., 2011). In
addition to the diagnostic potential, some lectins have antitumor
activity, mainly, targeting apoptosis pathways (Liu et al., 2010;
Fu et al., 2011). One of these antineoplastic lectins is Cramoll
1,4 (or pCramoll) extracted from the seeds of Cratylia mollis,
which showed an antitumor action in vivo against sarcoma 180
(Andrade et al., 2004). In order to avoid seasonal interference
and provide purer protein preparations, a recombinant lectin
(rCramoll) was heterologously expressed in Escherichia coli
(Varejão et al., 2010). This new lectin has the same ability to
agglutinate erythrocytes, monosaccharide specificity, and share
several other biophysical properties of native protein, however,
rCramoll seems to be more stable in denaturing situations
(Varejão et al., 2010, 2011).
Despite the anticancer potential of lectins, there are some
obstacles in using these macromolecules for this purpose, such
as the possible degradation by biological fluids, action on
unwanted targets, and the need for frequent doses to maintain
a therapeutic level (Cleland et al., 2001). These difficulties can
be overcome by the development of nanosystems, and one
good example is liposomes, vesicles consisting of one or more
lipid bilayers which may carry both hydrophilic, and lipophilic
drugs (Torchilin, 2011). Specifically, the stealth liposomes have
been shown as an effective tool for protein encapsulation due
to their higher circulation time and passive accumulation in
tumor tissues. All these beneficial effects of stealth liposomes
are related to the enhanced permeability and retention (EPR)
effect, whereby macromolecules can selectively and specifically
pass through the blood vessels that permeate the tumor and
accumulate only in these malignant tissues (Fang et al., 2011).
The improved permeability and retention are results of the
characteristic presence of leaky vascular system and disorganized
lymphatic system in malignant tumors (Sur et al., 2014). In this
context, the present work aimed to evaluate the in vivo antitumor
activity of rCramoll and rCramoll-loaded stealth liposomes.
MATERIALS AND METHODS
Materials
Soya phosphatidylcholine (Epikuron R© 200) and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene
glycol 2000; DSPE-PEG2000) were obtained from Lipoid
(Dusseldorf, Germany). Trehalose and Total Protein Peterson-
Lowry Kit were purchased from Sigma-Aldrich (St. Louis, USA).
The dialysis membrane (cut off 300 kDa) was purchased from
Spectrum Labs (USA). All other reagents used were of analytical
grade and purchased fromMerck (Darmstadt, Germany).
rCramoll Expression and Experimental
Factorial Design
rCramoll was obtained by heterologous expression using the
expression vector pET-28a-Cramoll and the strain E. coli Rosetta
(DE3), followed by purification using Sephadex G-75 column
as described by Varejão et al. (2010). A 24 full factorial design
was used to study the effects of some factors on the expression
level of soluble rCramoll: Cell density at induction measured
as optical density at 600 nm (OD600; 0.5 or 4.0), isopropyl-β-
D-thiogalactoside (IPTG) concentration (0.05 or 1mM), time
of induction (2 or 22 h), and temperature during the induction
(37 or 15◦C). The combinations resulted in eight different
expression experiments, which were performed in triplicate.
Three repetitions at the center point level (OD600: 2.25; 0.55mM
of IPTG, 26◦C and 11.5 h) were also performed to determine
if there is a non-linear relationship between the variables
and the responses. After the expression experiments, the E.
coli cells were harvested by centrifugation and disrupted by
sonication on ice (Varejão et al., 2010). Soluble and insoluble
fractions were separated by centrifugation and the presence of
recombinant Cramoll was analyzed by denaturing SDS-PAGE
electrophoresis. The protein concentration was quantified on
scanned gels using the Quantity One software (Bio-Rad). Purified
rCramoll was applied on gels at 5µM as a standard for the
quantification.
Hemagglutination Assays
The evaluation of hemagglutination activity (HA) was performed
using rabbit erythrocytes, following the protocol proposed by
Correia and Coelho (1995). Briefly, fresh erythrocytes from
rabbit were obtained from auricular vein, fixed in glutaraldehyde
and an erythrocytes suspension (2.5% v/v) was prepared in
NaCl 0.15 M. In parallel, each lectin was submitted to a two-
fold dilution (final volume of 50µL) in NaCl 0.15M using a
microdilution plate (V-bottom). Each well received 50µL of a
rabbit erythrocyte suspension. After 45min at room temperature,
the highest dilution with visible hemagglutination was recorded.
The HA was expressed in hemagglutination units (HU) which is
defined as the inverse of the highest dilution displaying visible
hemagglutination.
Evaluation of Functional Stability of
rCramoll after Ultrasound, Mechanical
Agitation and Cycles of Freezing and
Thawing
Samples of rCramoll (150µg/mL) were submitted to ultrasound
(200 W, 40Hz at 4◦C for 100, 250 and 300 s) and mechanical
agitation (150 rpm at 37◦C for 24 or 48 h). For the stability
test after cycles of freezing and thawing, rCramoll (1mL at
150µg/mL) in phosphate buffer (pH 7.4) was subjected up to 6
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cycles of freezing in liquid nitrogen (–196◦C) and thawing in a
water bath (35◦C). After these procedures, the hemagglutination
activity (HA) was evaluated. All these studies were performed in
triplicate.
Liposome Preparation
The liposomes were obtained by freeze-thaw technique (Pick,
1981). Briefly, lipids (phosphatidylcholine: Cholesterol: DSPE-
PEG2000) at the desired ratio (7.5:2:0.5) were dissolved in
a chloroform/methanol solution (3:1). Organic solvents were
removed under reduced pressure (37 ± 1◦C at 80 rpm) for
formation of the lipid film. After, the film was hydrated
with a solution of lectin (700µg/mL) in pH 7.4 phosphate
buffer (Andrade et al., 2004), and subjected to two cycles
of freezing and thawing for the formation of MLV’s (large
multilamellar liposomes vesicles), and finally sonicated for 25 s
(200 W, 40Hz and 4◦C) to obtain small unilamellar vesicles
(SUV).
Optimization and Stability Assessment of
Liposome Formulations
The optimization of particle size and polydispersity index (PI) of
liposome formulations were performed using different sonication
times (0, 10, 25, 50, and 100 s). The mean particle diameter and
polydispersity index of liposomes were determined by photon
correlation spectroscopy (PCS) using a laser particle size analyzer
DelsaTM Nano S (Beckman Coulter, UK). The surface charge
(zeta potential) of the vesicles was determined using a Zetatrac
Legacy (Microtrac R©, USA). Furthermore, the long-term stability
was evaluated by pH, particle size and polydispersity index
measurements after 7, 15, 30, 45, 60, and 90 days. For all analysis,
liposome samples (n = 3) were diluted in ultrapurified water
(25◦C) for particle counting. The results obtained are shown as
mean± standard deviation (SD).
Encapsulation Efficiency
To assess the rCramoll encapsulation effectiveness, an aliquot of
liposome (150µL) was diluted in 50µL of chloroform/methanol
solution (3:1) and sonicated for 7min. After, the volume was
adjusted to 1mL with Milli-Q water and the protein content was
measured by Peterson-Lowry Kit, following the manufacturer’s
instructions.
On the other hand, the measurement of unencapsulated
rCramoll was obtained using two approaches. The first consisted
in an ultracentrifugation of liposome formulation (256,860 ×
g for 30min; 4◦C, Beckman Optima LE-80K, rotor 70 ti),
followed by protein quantification in the supernatant. The second
methodology employed a dialysis separation using 300 kDa cut-
off membranes for 12 h with changes every 2 h, and finally, the
protein quantification was performed as described above.
Antitumor Activity
The in vivo antitumor activity was evaluated using Sarcoma-
180. Four groups (n = 7) were randomized into positive
and negative controls, rCramoll and rCramoll-loaded liposomes
treated groups. Ascitic tumor cells (5.0 × 106 cells/mL) were
inoculated subcutaneously (except for negative group) in the
right axillary region of male Swiss mice (40 g body average
weight; 40–60 days old). The treatment was started 24 h after
tumor inoculation and lasted for 7 consecutive days, through
one daily injection (7mg/Kg/day) of rCramoll, rCramoll-
loaded liposome or control group untreated (saline solution)
intraperitoneally administered (Andrade et al., 2004). After
treatment period, the animals were euthanized with Urethame R©
(1.25 g/kg body weight) and sacrificed by cardiac puncture. The
antitumor activity was calculated using this formula:
Tumor inhibition (TI%) : TI% = [(C− T)/C] × 100,
where C is the mean tumor weight of the control group and T is
the mean tumor weight of treated groups.
Experiments involving animals were performed 25 ± 2◦C
on 12 h light/12 h dark cycles with free access to water and
food. All animal experiments were performed as proposed by
ethical standards of Universidade Federal de Pernambuco and
were approved by its ethics committee (CEUA/UFPE; protocol
23076.023165/2012-13).
Histopathological Analysis
At the end of the treatment phase, the tumor and some organs
(liver, spleen, kidneys) were fixed in 10% neutral buffered-
formalin solutions (24 h) and subsequently immersed in paraffin.
Sections (3–5µm) were prepared and slides were mounted for
histological analysis. Slides were stained with hematoxylin and
eosin and observed under a light microscope (Nikon-E200,
Nikon Instruments). The mitotic index (MI) was determined
evaluating mitosis number per field in each experimental group.
Control animals were considered as 100%. Photomicrographs
were evaluated using the ImageJ (version 1:44; Research Services
Branch, USA).
Hematological and Biochemistry Analysis
Blood samples were collected in MiniCollect R© K3EDTA tubes
(Greiner Bio-One, Austria) for hematological analysis, which
included the determination of hemoglobin concentration
(Hb), hematocrit (Ht), mean corpuscular volume (MCV),
mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), white blood cells (WBC),
and red blood cells (RBC; SYSMEX XT-4000iTM automated
hematology analyzer, Sysmex America, Inc.). The plasma levels
of aspartate aminotransferase (AST), alanine aminotransferase
(ALT), urea and glucose were determined using COBAS R©
6000 automated analyzer (Roche Diagnostics, England).
Additionally, the glutathione peroxidase (GPX) activity was
estimated using Ransel Glutathione Peroxidase kit (Randox
Laboratories, United Kingdom), according to the manufacturer’s
instructions.
Statistical Analysis
Data were analyzed by one-way analysis of variance (ANOVA)
and Tukey test to determine the statistical significance using
GraphPad Prism (GraphPad Software, Inc., San Diego, CA,
versão 6.03). A p-value of< 0.05 was considered to be statistically
significant. All data are represented as mean value ± standard
deviation.
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RESULTS
rCramoll Expression and Experimental
Factorial Design
An important challenge for high level expression of heterologous
proteins in E. coli is the formation of inclusion bodies (Varejão
et al., 2010). We investigated through experimental factorial
design the effects of four culture conditions factors (such as
induction cell density, IPTG concentration, temperature and
time of induction) known to influence protein expression
in E. coli. The results showed that the highest ratios of
soluble/insoluble rCramoll were obtained in assays 1 and 3.
In these two assays, the induction occurred at the lowest
temperature of induction (15◦C) and lowest cell density (0.5). A
linear relationship between the tested variables and responses was
found as the ratios observed for the center point level assays were
within the value range obtained for each responses of the eight
independent assays (Table 1 and Figure A1).
Pre-formulation Assessment of rCramoll
Functional Stability
All parameters of liposome preparation must ensure high drug
encapsulation efficiency and preservation of biological activity
of target protein (Walde and Ichikawa, 2001). In this context,
evaluations of the influence of ultrasound, mechanical agitation,
and freezing-thawing cycles on HA levels of rCramoll were
performed after the formulation of liposomes. Samples submitted
to ultrasound until 250 s did not show changes in their HA as
compared to untreated rCramoll (256−1). Similarly, the HA of
this protein was only altered after 48 h of mechanical agitation. In
addition, the HA remained unchanged after 2 cycles of freezing-
thawing (Table 2).
Characterization of rCramoll-Loaded
Stealth Liposomes
Based on the pre-formulation results, rCramoll-lipo were
prepared using two freezing-thawing cycles and then submitted
to different times of ultrasound (0–100 s). Taking into account
that liposomes with size less than 200 nm have been described
as appropriate for antitumor therapy (Allen and Cullis, 2013),
the best formulation with a homogeneous size distribution was
obtained after 25 s of sonication, showing the size of 168.0 ±
0.7 nm and PI of 0.265± 0.025, zeta potential of−31.9± 0.1mV
and pH 7.4 (Table 3).
Liposomes showed a long-term stability, after 90 days they
continued in appropriate size (170.1 ± 2.0 nm), PI of 0.320 and
pH of 7.3. The encapsulation efficiency of rCramoll evaluated
by dialysis and ultracentrifugation were 57.3 ± 0.3% and 59.3
± 1.5%, respectively. No statistical differences were observed
between them (p < 0.05) (Table 4).
Antitumor Activity of rCramoll and
rCramoll-Loaded Stealth Liposomes
Figure 1 shows the antitumor activity of rCramoll and rCramoll-
loaded stealth liposomes on mice transplanted with sarcoma 180
tumors. Both free and encapsulated rCramoll treatments resulted
in high levels of in vivo tumor growth inhibition. rCramoll
showed antitumor activity of 59% with a reduction of 0.82 ±
0.17 g in tumor mass. On the other hand, the encapsulation of
rCramoll in stealth liposomes promoted a greater reduction in
tumor mass (0.50± 0.10 g) resulting in 75% of growth inhibition.
In other words, rCramoll-lipo was 16% more efficient than free
lectin (p < 0.05).
Histopathological Analysis
Regardless of the group studied, the tumor invaded muscle,
bone and fat tissue. Areas of necrosis and hemorrhage were
also observed. The neoplastic cells were predominantly arranged
in solid pattern, pleomorphic, large, with abundant cytoplasm
and without defined borders. A significant inhibition of cell
division (mitotic index) was observed in the animals treated
with rCramoll-lipo (∼5%, in relation to control group);
otherwise, rCramoll promoted more cell proliferation (13.76%)
in relation to untreated animals (p < 0.05; Figure 2).
Histopathological analysis of selected organs of animals treated
with rCramoll and rCramoll-lipo groups showed no changes
in kidneys and spleen morphology. However, vacuolization
areas were observed in hepatocytes from animals treated
TABLE 1 | Experimental design matrix and response for expression of soluble rCramoll in Escherichia coli.
Assay Cell density (OD600) IPTG Concentration (mM) Temperature of induction (
◦C) Time of induction (h) Ratio of soluble/insoluble
rCramoll
1 0.5 0.1 15 21 1.27
2 4.0 0.1 15 2 0
3 0.5 1.0 15 2 0.83
4 4.0 1.0 15 21 0
5 0.5 0.1 37 2 0
6 4.0 0.1 37 21 0
7 0.5 1.0 37 21 0
8 4.0 1.0 37 2 0
9 (C) 2.25 0.55 26 11.5 0.41
10 (C) 2.25 0.55 26 11.5 0.34
11 (C) 2.25 0.55 26 11.5 0.20
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TABLE 2 | Effects of ultrasound, mechanical agitation, and cycles of
freezing and thawing on hemagglutination activity of rCramoll.
Parameter Hemagglutination activity
(HA/50 µL)a
Time of mechanical agitation (h) 0 256−1
24 256−1
48 128−1
Time of ultrasound (s) 0 256−1
100 256−1
250 256−1
300 128−1
Cycles of freezing and thawing 0 128−1
1 128−1
2 128−1
3 32−1
4 32−1
5 32−1
6 32−1
aThe value is expressed as hemagglutination titer, defined as the reciprocal of the highest
dilution exhibiting visible hemagglutination.
TABLE 3 | Effects of ultrasound on the stability of rCramoll in stealth
liposomes.
Ultrasound time (s)
0 10 25 50 100
Particle size
(nm)
443.6 ± 34.7 230.7 ± 3.9 168.0 ± 0.7 106.1 ± 4.2 88.3 ± 0.4
Polydispersity
index
0.463 0.299 0.265 0.226 0.219
TABLE 4 | The encapsulation efficiency of rCramoll in stealth liposomes.
Method Teor (%) Encapsulation efficiency (%)
Dialysis 95.82 ± 0.79 57.3 ± 0.3
Ultracentrifugation 95.82 ± 0.79 59.3 ± 1.5
with encapsulated lectin, suggesting the presence of early
steatosis and microabscess, both related to inflammatory process
(Figure 3).
Hematological and Biochemistry Analysis
Analysis of hematological parameters (Table 5) of control and
treated animals revealed interesting alterations: All experimental
groups showed significant changes in relation to healthy animals.
rCramoll treated group exhibited an increase in leukocyte
number (8.1 ± 3.0 103/µL) when compared with both normal
(3.2 ± 0.12 103/µL) and untreated animals (11.4 ± 1.7 103/µL).
Surprisingly, the lectin encapsulation had a stronger effect on
leukocyte number (17.1 ± 3.2 103/µL), which represented an
increment of 111.11%. Other cellular parameters (Ht, MCV,
MCH, Hb, MCHC, WBC, RBC) were virtually unaltered by
treatment.
No significant changes in urea or glucose level were seen
between any sarcoma 180 tumor-transplanted animals (treated
or untreated) and healthy animals (p < 0.05); discarding
possible kidney damage. On the other hand, the enzymatic
activity of aspartate aminotransferase was significantly reduced
in animals treated with free (183.5 ± 5 IU/L) or encapsulated
lectin (217 ± 3 IU/L) when compared to untreated group
(276 ± 19 IU/L). Regarding alanine aminotransferase activity,
treatment-related effects were observed and their levels were
not significantly different than the control group, except for
encapsulated rCramoll treated group, which showed a significant
reduction (9.4 ± 4.0 IU/L; Table 5). Furthermore, the levels of
glutathione peroxidase were not altered by both treatments with
rCramoll or its encapsulated form (Figure 4).
DISCUSSION
New molecular approaches using modified microorganism have
been developed for production of recombinant proteins, allowing
them to be used as research, therapeutic and diagnostic tools
(Pina et al., 2013). Specifically, the heterologous expression of
rCramoll and other bioactive lectins offer some advantages such
as any seasonal interference or plant collection, production of
high amounts of proteins with defined amino-acid sequences
(excluding the presence of different isoforms) leading to more
precise biomedical properties (Varejão et al., 2010; Oliveira
et al., 2014). rCramoll was expressed using a sophisticated
approach which resulted in a functional protein with several
physicochemical properties (molecular mass, charge density,
sugar specificity and tertiary structures) similar to its native
counterpart. However, a little enhancement in stability to
acidification, high temperatures and hydrostatic pressure were
observed (Varejão et al., 2011).
A strong antitumor action has been reported for pCramoll
(native protein) free and loaded in conventional liposomes
(Andrade et al., 2004). These authors showed that the
encapsulation of pCramoll improved its antitumor activity (30%)
and decreased its tissue toxicity (particularly, in the liver and
kidney). Taken together, these factors pointed to the need to
evaluate the antitumor action of the new lectin rCramoll. For
this purpose the nanoencapsulation of rCramoll into stealth
liposome was employed to improve its therapeutic ratio as a
result of EPR effect, which reduces drug concentrations in normal
tissues and raises their concentrations in tumors (Sur et al.,
2014). The EPR phenomenon has become the gold standard
in the design of anticancer agents (Fang et al., 2011; Torchilin,
2011).
The first step was to evaluate the effects of encapsulation
parameters in rCramoll functional stability by HA. The results
showed that rCramoll was stable up to 2 freezing-thawing cycles,
250 s of ultrasound and 48 h of mechanical agitation. The results
were similar to those found for pCramoll (Andrade et al., 2004).
Then, an encapsulation ratio of 60% was obtained after 2 cycles
of freezing-thawing, without altering rCramoll stability. The
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FIGURE 1 | Effects of rCramoll and rCramoll-loaded stealth liposomes (rCramoll-lipo) on weight of sarcoma 180 tumors. *(p < 0.05).
FIGURE 2 | Analysis of cell division in tumor tissue from untreated animals (A) and treated with rCramoll (B) and rCramoll-loaded stealth liposomes
(C). Cell division (mitosis) are indicated by arrow.
freeze-thaw technique is widely used to encapsulate hydrophilic
molecules into liposomes, and it is appropriate to increase the
internal volume of these vesicles (Sriwongsitanont and Ueno,
2011).
In this work, liposomes were formulated with 5% of PEG
(polyethylene glycol) to ensure stealth nanosystems for in vivo
application (Dos Santos et al., 2007). However, the addition of
PEG can influence the encapsulation efficiency of hydrophilic
macromolecules because of the presence of the PEG chains
within the vesicles which may restrict the available of internal
space for encapsulation (Nicholas et al., 2000), this may explain
the reduction about 26% observed in rCramoll encapsulation
efficiency in stealth liposomes, compared to Andrade et al. (2004)
for pCramoll in conventional liposomes.
Proteins are macromolecules bigger than conventional drugs,
and several parameters influence the performance of their
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FIGURE 3 | Histopathological analysis of liver from untreated animals (A) and treated with rCramoll (B) and rCramoll-loaded stealth liposomes (C).
Vacuolization areas are indicated by arrow.
TABLE 5 | Hematological and biochemistry analysis of blood samples of mice treated with rCramoll and rCramoll-lipo.
Parameters Treatments
Healthy Untreated (Saline) rCramoll rCramoll-lipo
Hb (g/dL) 18.5 ± 0.05 12.6 ± 2.4‡ 13.4 ± 1.3‡ 10.3 ± 3.1‡,*
Ht (%) 51.0 ± 0.44 39.1 ± 7.3‡ 40.7 ± 3.8‡ 31.3 ± 9.8‡
MCV (µm3 ) 52.8 ± 0.49 50 ± 1.7‡ 47 ± 0.5‡ 48 ± 1.4‡
MCH (pg) 17.8 ± 0.05 16 ± 0.5‡ 15.6 ± 0.2‡ 15.8 ± 0.3‡
MCHC (g/dL) 33.4 ± 0.57 32.4 ± 0.3‡ 33.0 ± 0.2‡,* 33.0 ± 0.4‡
RDW (%) (106/µL) 10.4 ± 0.03 7.93 ± 1.6‡ 8.6 ± 0.9‡ 6.56 ± 2.1‡,*
WBC (103/µL) 3.2 ± 0.12 11.4 ± 1.7‡ 8.1 ± 3.0‡ 17.1 ± 3.2‡,*
Glucose (mg/dL) 116.1 ± 10.4 178.3 ± 36.2 148.5 ± 26.0 177.7 ± 43.9
Urea (mg/dL) 27.67 ± 3.78 37.6 ± 15.5 35.5 ± 5.3 33.8 ± 3.3
AST (U/L) 79.43 ± 7.50 276 ± 19‡ 183 ± 50‡,* 217 ± 30‡,*
ALT (U/L) 31.4 ± 2.1 20.4 ± 3.6 25.7 ± 18.5 9.4 ± 4.0‡,*
‡
Significant differences in relation to control; * Significant differences in relation to control (saline) treated animals. Legend: Hemoglobin concentration (Hb), hematocrit (Ht), mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cells (WBC), red blood cells (RBC), aspartate
aminotransferase (AST), and alanine aminotransferase (ALT).
encapsulation, including the concentration of lipids and size
(diameter) of the liposomes (Hwang et al., 2012). The increase in
lipid concentration results in a greater inner volume; therefore, in
this study liposomes were prepared using 80mM. Additionally,
the diameter of vesicles was 168 ± 0.7 nm, which is considered
within the optimal range (<200 nm) for antitumor therapy due
to the capacity to accumulate passively in sites with increased
vascular permeability (Allen and Cullis, 2013). The PDI of
the liposomal formulation was 0.265, this parameter evaluates
the size distribution having a value between 0 and 1 (the
value 0 indicates the proximity of monodisperse particles; Jain
et al., 2012). After the establishment of the best parameters
for the formulation of rCramoll-lipo, the antitumor potential
of this nanosystem and free lectin were evaluated. They were
intraperitoneally administered. The administration of substances
into the peritoneal cavity (a parenteral route) is common in
laboratory rodents for which intravenous access can be used to
safely inject large volumes of fluid. Once in blood circulation,
the agent (compound or a formulation) may be conducted for
different areas in the body, including for the subcutaneous tumor
area (which is highly vascularized; Turner et al., 2011). This
route has been widely used for in vivo evaluations of antitumor
FIGURE 4 | Effects of rCramoll and rCramoll-lipo on serum levels of
gluthathione peroxide.
activity (Goh et al., 2015; Ferreira et al., 2016; Silveira et al.,
2016).
Our results revealed that the tumor inhibition induced by
lipo-rCramoll was 16% higher than free rCramoll. Additionally,
antitumoral activity of free rCramoll was more potent when
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compared with the previous results reported by Andrade et al.
(2004) for free pCramoll. On the other hand, even with
an encapsulation efficiency 20% lower than pCramoll-lipo,
similar results were found between rCramoll-lipo and pCramoll-
lipo antitumor activities, advocating thereby for a stronger
action of rCramoll-lipo (Andrade et al., 2004). The improved
activity of drugs in stealth liposomes has been shown for
other antitumor agents, for example, gemcitabine hydrochloride
showed improved pharmacokinetics and residence time, and
reduced blood toxicity (Pitrubhakta et al., 2012).
Another important parameter to an antitumor agent is the
mitotic index which revealed that the encapsulation of rCramoll
was able to prevent the induction of tumor proliferation (p <
0.05), while free rCramoll induced cell division. The mitogenic
action of free pCramoll has been related to its well-known
immunomodulatory potential (Nascimento da Silva et al., 2014).
On the other hand, as nanosystem (stealth liposomes) provided
drug delivery in a controlled manner, rCramoll-lipo seems to
be more effective on acting in the recruitment of immune cells
culminating in tumor reduction. In fact, animals treated with
encapsulated protein exhibited an increase in the leukocyte
number when compared with others groups. Inflammation
mediated by leukocytes is an essential immune response to
perturbed tissue homeostasis and plays decisive roles at different
stages of tumor growth, affecting the responses to therapy
(positively or negatively; Mantovani et al., 2008). For example,
both chemotherapy and radiation kill cancer cells mostly through
necrosis, a proinflammatory form of cell death, while several anti-
inflammatory drugs have been found to reduce tumor incidence
(Grivennikov et al., 2010). Previous studies have indicated that
pCramoll is an immunomodulatory agent able to induce Th1
and Th17 responses (Nascimento da Silva et al., 2014). Recently,
the immunomodulatory potential of rCramoll has been also
demonstrated using mouse peritoneal exudate cells (mPECs).
rCramoll treatment significantly enhanced the production of
proinflammatory cytokines by PECs (IL-1β, IL-6, IFN-γ, and
TNF-α) and nitric oxide (NO; da Silva et al., 2015). Therefore, at
this point, a crucial difference between the anti-tumor action of
free and encapsulated rCramoll was found along with their effects
on immune cells.
Concerning the effects of both treatments on kidneys, no
significant alterations were observed in the urea level and
kidneys morphology. Likewise, the levels of AST were unaltered
among the different experimental groups. However, a significant
decrease in ALT levels was observed in the group treated
with the encapsulated lectin. The histopathological analysis
showed the presence of inflammatory infiltrates and areas
of microsteatosis in the liver of animals treated with the
encapsulated rCramoll, however, interstitial fibrosis, necrosis, or
parenchymal involvement were not observed in this group. In
fact, in a study of biodistribution, large quantities of pCramoll
were found in the liver of animals (Patricio et al., 2011). Thus,
without the occurrence of more serious damage, the liver is
capable of promoting its regeneration (Scheuer, 2003).
Finally, any treatment-related effects were observed in the
levels of glutathione peroxidase. This enzyme is an important
component of the antioxidant defense system, and as tumor cells
generally produce much more reactive oxygen than normal cells,
the expression of protective enzymes may be compromised in
some cancers (Falck et al., 2010). However, other studies also
showed that, in some types of tumor cells, a decreased expression
of glutathione peroxidase can enhance tumor suppressor effect
of manganese enzyme superoxide dismutase (MnSOD), which
is another important antioxidant enzyme (Liu et al., 2004). It is
worth noting that the induction of reactive oxygen species (ROS)
by pCramoll has been demonstrated in several murine models
(Nascimento da Silva et al., 2014), and rCramoll is also able to
increase the in vitro ROS production by mPECs (da Silva et al.,
2015). Both lectins are able to induce cell proliferation even in
cells exposed to oxidative stress (Nascimento da Silva et al., 2015).
Given the action of both free rCramoll and rCramoll-lipo on
leukocytes proliferation, ROSmay be involved in the antitumoral
action of lectin, and they would act oxidizing glutathione and
consequently inhibiting the action of GPX. Induction of free
radicals is related to the activity of many antitumor drugs
(Lampiasi et al., 2012; Chung et al., 2013). Other tests should
also be performed in order to investigate involvement of ROS in
anti-tumor capacity of rCramoll.
CONCLUSION
In conclusion, the encapsulation of rCramoll in stealth liposomes
improves its antitumor activity without substantial toxicity.
This approach was more successful than the previous results
reported for pCramoll loaded into conventional liposomes.
Additionally, the effects of lectin in the mitotic index were also
prevented by encapsulation. The enhancement on antitumoral
action seems to be related to increment of leukocytes account
during the encapsulated rCramoll treatment. Therefore, further
investigations are required to elucidate the mechanism(s) of the
rCramoll antitumor effect.
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APPENDIX
FIGURE A1 | Analysis of the soluble recombinant rCramoll produced by E.
coli at the optimal culture conditions (Cell density of 0.5; IPTG at 0.1mM;
induction at 15◦C and for 21h. 1-Total production of rCramoll in E. coli;
2-rCramoll in E. coli soluble fraction; 3-rCramoll in E. coli insoluble fraction;
4-Previously purified rCramoll (5µM) used as a standard for the quantification.
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